Evidence map›Paper›PMID 31703407›Full record

ArticleCancers2019

[

Olga Sergeeva, Vladimir Kepe, Yifan Zhang, Galen A Miller-Atkins, Jonathan D Keynon, Renuka Iyer, Sandra Sexton, Amad Awadallah, Wei Xin, Yogen Saunthararajah and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Fluorinated carbohydrates forChemical Society reviews · 2023
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Olga SergeevaRadiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Vladimir KepeNuclear Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Yifan ZhangRadiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Galen A Miller-AtkinsInstitute for Computational Biology, Cleveland, OH 44106, USA.
Jonathan D KeynonBiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Renuka IyerMedical Oncology, Rowell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sandra SextonMedical Oncology, Rowell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Amad AwadallahPathology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Wei XinPathology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
Yogen SaunthararajahHematology & Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
E Ricky ChanInstitute for Computational Biology, Cleveland, OH 44106, USA.
Zhenghong LeeRadiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Case Western Reserve University · USCleveland Clinic · USUniversity Hospitals of Cleveland · US

Funding

Imaging Liver Cancer ProliferationR01CA204373 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LEE, ZHENGHONG, SAUNTHARARAJAH, YOGEN · 2016 to 2021
$1.8M
National Cancer Center R01CA204373NCI NIH HHS R01 CA204373
6 · The paper itself

Abstract

Clinical diagnosis of hepatocellular carcinoma (HCC) relies heavily on radiological imaging. However, information pertaining to liver cancer treatment such as the proliferation status is lacking. Imaging tumor proliferation can be valuable in patient management. This study investigated

Indexed as

hepatocellular carcinomaPET imagingtumor proliferation

Identifiers

PMID31703407
PMCPMC6896045
OpenAlexW2983881270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.